Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl

被引:2
作者
Suen, Leslie W. [1 ]
Chiang, Amy Y. [1 ]
Jones, Benjamin L. H. [2 ]
Soran, Christine S. [3 ]
Geier, Michelle [3 ]
Snyder, Hannah R. [4 ]
Neuhaus, John [5 ]
Myers, Janet J. [5 ]
Knight, Kelly R. [6 ]
Bazazi, Alexander R. [7 ]
Coffin, Phillip O. [3 ]
机构
[1] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Gen Internal Med, San Francisco, CA USA
[2] Univ Calif Los Angeles, Dept Med, Los Angeles, CA USA
[3] San Francisco Dept Publ Hlth, San Francisco, CA USA
[4] Univ Calif San Francisco, Dept Family Med, San Francisco, CA USA
[5] Univ Calif San Francisco, Dept Biostat& Epidemiol, San Francisco, CA USA
[6] Univ Calif San Francisco, Dept Humanities & Social Sci, San Francisco, CA USA
[7] Univ Calif San Francisco, Dept Psychiat & Behav Sci, San Francisco, CA USA
关键词
OPIOID USE DISORDER; MAINTENANCE THERAPY; SUBSTANCE USE; METHADONE; FORMULATIONS; INDUCTION; OVERLAP;
D O I
10.1001/jamanetworkopen.2024.56253
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Importance The rise of high-potency opioids such as fentanyl makes buprenorphine initiation challenging due to the risks of precipitated withdrawal, prompting the exploration of strategies, such as low-dose initiation (LDI) of buprenorphine. However, no comparative studies on LDI outcomes exist. Objective To evaluate outpatient outcomes associated with 2 LDI protocols of buprenorphine among individuals with opioid use disorder (OUD) using fentanyl. Design, Setting, and Participants This cohort study analyzed data on adults with OUD who self-reported daily fentanyl use and underwent buprenorphine initiation using LDI. Data were extracted from the electronic health records of 2 substance use disorder treatment clinics using a specialty behavioral health pharmacy in San Francisco, California, from May 2021 to November 2022. Exposures Type of LDI protocol selected by individuals: 4-day or 7-day protocol. Main Outcomes and Measures The primary outcome was successful buprenorphine initiation, defined as self-reported LDI completion and pickup of a refill maintenance prescription, and buprenorphine retention. Logistic regression with generalized estimating equations assessed associations between LDI protocol (4-day vs 7-day) and successful initiation, adjusting for multiple attempts, age, gender identity, race and ethnicity, and housing status. Kaplan-Meier survival curves were used to estimate buprenorphine retention, and survival curves were adjusted using a fitted Cox proportional hazards regression model. Results A total of 126 individuals (median [IQR] age, 35 [29-44] years; 90 identified as men [71%]; 26 [21%] identified as Black or African American, 20 [16%] as Latine, and 66 [52%] as White individuals) with 175 initiation attempts were included. Across attempts, 72 (41%) had a 4-day LDI protocol and 103 (59%) had a 7-day protocol. Initiation was successful in 60 attempts (34%), including 27 (38%) among 4-day protocol and 29 (28%) among 7-day protocol attempts. Buprenorphine retention rate at 28 days was 21% for a 4-day protocol and 18% for a 7-day protocol. Logistic regression found no significant differences between LDI protocols and successful initiation, while repeated LDI attempts had lower odds of success (second attempt: adjusted odds ratio [AOR], 0.30 [95% CI, 0.14-0.66]; third or more attempt: AOR, 0.22 [95% CI, 0.09-0.53]). Unadjusted and adjusted survival models did not detect a significant difference in retention between LDI protocol types. Conclusions and Relevance This cohort study found that among people with OUD using fentanyl and attempting outpatient LDI of buprenorphine, successful buprenorphine initiation and retention rates were low. Future studies should examine interventions to improve LDI success and increase buprenorphine uptake and retention.
引用
收藏
页数:13
相关论文
共 54 条
  • [1] Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review
    Adams, K. K.
    Machnicz, M.
    Sobieraj, D. M.
    [J]. ADDICTION SCIENCE & CLINICAL PRACTICE, 2021, 16 (01)
  • [2] Ahmad F., Provisional drug overdose death counts
  • [3] Microinduction of Buprenorphine/Naloxone: A Review of the Literature
    Ahmed, Saeed
    Bhivandkar, Siddhi
    Lonergan, Brady B.
    Suzuki, Joji
    [J]. AMERICAN JOURNAL ON ADDICTIONS, 2021, 30 (04) : 305 - 315
  • [4] Anderson N., 2023, Substance use trends in San Francisco through 2022
  • [5] [Anonymous], 2004, CLIN GUIDELINES USE
  • [6] [Anonymous], 2023, Removal of DATA waiver (X-Waiver) requirement
  • [7] Continued Increases in Overdose Deaths Related to Synthetic Opioids Implications for Clinical Practice
    Baldwin, Grant T.
    Seth, Puja
    Noonan, Rita K.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (12): : 1151 - 1152
  • [8] Low Dose Buprenorphine Induction With Full Agonist Overlap in Hospitalized Patients With Opioid Use Disorder: A Retrospective Cohort Study
    Bhatraju, Elenore P.
    Klein, Jared W.
    Hall, Allana N.
    Chen, David R.
    Iles-Shih, Matthew
    Tsui, Judith, I
    Merrill, Joseph O.
    [J]. JOURNAL OF ADDICTION MEDICINE, 2022, 16 (04) : 461 - 465
  • [9] Fentanyl Absorption, Distribution, Metabolism, and Excretion: Narrative Review and Clinical Significance Related to Illicitly Manufactured Fentanyl
    Bird, H. Elizabeth
    Huhn, Andrew S.
    Dunn, Kelly E.
    [J]. JOURNAL OF ADDICTION MEDICINE, 2023, 17 (05) : 503 - 508
  • [10] Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder
    Bjornsson, Marcus
    Acharya, Chayan
    Strandgarden, Kerstin
    Tiberg, Fredrik
    [J]. CLINICAL PHARMACOKINETICS, 2023, 62 (10) : 1427 - 1443